The initial focus for the infection leadership team is on hospital acquired infection (HAI) which is a leading cause of morbidity and mortality and impact of the cost of care delivery in acute healthcare facilities. It is estimated that there are about 200,000 HAIs each year in Australia, thus the most common complication affecting patients in hospital. Whilst, rates of HA Staphylococcus aureus infections have fallen over the last decade in Australia, other HAIs have increased. This requires focused and novel approaches to strategies in hospitals to mitigate the risks of HAI, including study of risk factors for person-to-person spread of pathogens, ways to decrease bloodstream infections and other HAIs and understanding the processes and drivers of antibiotic prescribing and oversight via antimicrobial stewardship programs.
As in other medical fields, the availability of next generation sequencing techniques is revolutionising diagnostics of infectious diseases. The diagnosis of microbial origin of diseases has been traditionally based on the demonstration of the presence of a given pathogen in a given clinical sample. There is an opportunity to collaboratively develop pathways and informatics platforms that will allow profound changes in routine laboratory practice for microbiological diagnosis.
The aim is to reduce hospital acquired infections by:
Working together, a team of investigators in immunity will build on existing preclinical successes in vaccination, antigen-specific, targeted and cellular immunotherapies for treatment of autoimmune disease infection and cancer. The group have very strong clinical and industry partnerships, which have resulted in product development and clinical trials. They will leverage existing pre-clinical animal models, clinical cohorts, biobanks, immunomonitoring platforms, rapid genomic screening platforms for antigen identification, and nanoparticle technologies. Further preclinical research will enable innovative clinical trials of personalised antigen-specific and immunomodulatory immunotherapies in susceptible cancers and organ-specific autoimmune diseases. The group is closely aligned with consumers and will work with health economists and clinicians specialising in primary care, oncology, rheumatology and endocrinology to enhance implementation of personalised immunotherapeutics. They will leverage this highly translational theme to maximise opportunities for research training at the interface between basic and clinical science.
The aim is to prevent and safely control autoimmune diseases and susceptible cancers by:
Inflammation is associated with autoimmune diseases, severe infections and many chronic disorders. The team of investigators of basic and clinical immunologists will build on existing expertise to development new antigen-specific and immunomodulatory immunotherapies therapies to suppress pro-inflammatory immune cells and enhance immune tolerance. For more information contact email@example.com
Health Translation Queensland acknowledges the Traditional Owners and their custodianship of the lands on which we live, work, and play. We pay our respects to their Ancestors and their descendants, who continue cultural and spiritual connections to Country. We recognise their valuable contributions to Australian and global society.
© 2023 Health Translation Queensland Site by NWO